Company Overview and News

1
Cannabix Technologies Files FAIMS Cannabis Detection Patent - Enters into License Agreement with University of Florida and Provides Technology Update

2018-04-16 globenewswire
VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE:BLO) (OTC PINK:BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report it has filed a Patent Cooperation Treaty (“PCT”) application titled, “Device and Method for Detection of Cannabis and Other Controlled Substances Using FAIMS” (PCT/CA2017/000042).

 
269 Marijuana Stocks: Correction, Crash, Or Slow Descent?

2018-02-22 seekingalpha
I have been on the planet for 60+ years, and this is starting to look more like a general market “crash” than a “correction”.

1
Cannabix Technologies: 98% Speculation On This Marijuana Stock

2018-01-11 seekingalpha
Cannabix Technologies' (OTCPK:BLOZF) current price is ~$250 million, while its adjusted book value only shows ~$3 million in value. Any perceived value over the $3 million is speculation of BLO's prospects. Because of the uncertainty and low barriers to entry in the marijuana breathalyzer space, I consider a ~$250 million price tag dramatically expensive. Even if BLO is able to bring its breathalyzer to market first, there is no guarantee for long-term success.

1
Horizons Marijuana Life Sciences Index ETF Is A Best Bet For The Passive Marijuana Investor

2018-01-03 seekingalpha
It is always difficult to “pull the trigger” and buy a stock or other financial instrument after a “gap up,” but put this ETF on your “watch list.”.

1
Upcoming Seasonal Anomalies: A Marijuana Stock Focus

2017-11-21 seekingalpha
I was really pleased to see Ted Ohashi focusing on Tax Loss Selling in his most recent Seeking Alpha article, and thought readers might find this article of interest.

1
Cannabix Technologies Inc. Announces Upsize of Previously Announced Bought Deal Private Placement to $4,025,000 and Concurrent Non-Brokered Private Placement of $977,500

2017-11-20 marketwired
Cannabix Technologies Inc. (CSE:BLO)(CSE:BLO.CN)(CNSX:BLO) (the "Company") is pleased to announce that it has amended its agreement with Cormark Securities Inc. (the "Underwriter") and has agreed to increase the size of its previously announced $3.45 million "bought deal" private placement offering. Pursuant to the upsized deal terms, the Underwriter has agreed to purchase, on a "bought deal" basis, 3,500,000 units ("Units") in the capital of the Company, at a price of $1.

1
Cannabix Technologies Inc. Announces $3.45 Million Bought Deal Private Placement

2017-11-17 marketwired
NOT FOR DISTRIBUTION TO UNITED STATED NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES AND DOES NOT CONSTITUTE AN OFFER IN THE UNITED STATES OF THE SECURITIES DESCRIBED HEREIN

 
Dangerous Opinions Spur Need for Cannabis Breathalyzer -- CFN Media

2017-11-09 marketwired
SEATTLE, WA--(Marketwired - Nov 9, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Cannabix Technologies Inc. (CSE: BLO) (CNSX: BLO) (BLO.CN) (OTCQB: BLOZF), its recent patent filing for a cannabis ignition interlock device, as well as its continued progress in developing a roadside cannabis breathalyzer.

 
Cannabix: Capitalize on Pent-Up Demand for Cannabis Breathalyzer -- CFN Media

2017-08-14 marketwired
SEATTLE, WA--(Marketwired - Aug 14, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) and its upcoming marijuana breathalyzer designed to help law enforcement detect the presence of tetrahydrocannabinol ("THC") at roadside and ultimately prosecute offenders.

 
Cannabix Set to Begin Trials in BC with New Hire -- CFN Media

2017-06-13 marketwired
SEATTLE, WA--(Marketwired - Jun 13, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces an article discussing Cannabix Technologies Inc. (CSE: BLO) (OTCQB: BLOZF) and its efforts to develop a highly sensitive marijuana breathalyzer using its patented FAIMS technology.

 
Cannabix Technologies Adds Dr. David Hasman to Initiate Marijuana Breathalyzer Trials in British Columbia

2017-05-25 marketwired
The Cannabix Marijuana Breathalyzer is being developed to give law enforcement and employers a tool to enforce public safety

 
Competition Heating Up In The Cannabis Breathalyzer Space

2017-05-24 seekingalpha
Cannabix Technologies Inc. has been developing the Cannabix Marijuana Breathalyzer for use by law enforcement and in the workplace.

 
Marijuana & Driving: A Review of the Studies & Legal Challenges -- CFN Media

2017-05-01 marketwired
SEATTLE, WA--(Marketwired - May 1, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an article discussing the studies for and against marijuana impaired driving, the current state laws regarding per se limits, the challenges for state regulators and law enforcement, and upcoming solutions like Cannabix Technologies' (OTC PINK: BLOZF) cannabis breathalyzer.

 
Cannabix Looks to Solve Roadside THC Testing Issues -- CFN Media

2017-04-12 marketwired
SEATTLE, WA--(Marketwired - Apr 12, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an article discussing Cannabix Technologies Inc.'s (CSE: BLO) (OTC PINK: BLOZF) recent progress in developing a roadside THC breathalyzer.

 
Live Testing with Cannabix Marijuana Breathalyzer Shows Excellent Sensitivity for THC and Related Metabolites

2017-03-27 marketwired
The Cannabix Marijuana Breathalyzer is being developed to give law enforcement and employers a tool to enforce public safety

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...